Articles by Sergey Klimenko



B2B: Parallel Import of Medicines: High Time or the Wrong Time?

  • 15 June 15
  • Pepeliaev Group
Russia is still heavily dependent on foreign medicines.

B2B: Foreign Medical Device Manufacturers: Should You Stay or Should You Go?

  • 15 September 14
  • Pepeliaev Group
Although the conditions for entering the market have been reshaped, the legislation is about to give investors tools they never had before.

B2B: User-Friendly Legal Interface for the Life Sciences Market

  • 08 October 13
  • Pepeliaev Group
Quite often, when describing the situation with regulating a specific Russian industry, we could construct analogies with the world of software, where the legislator (the actual regulator) is the designer, the law is the program, and the market players are the ever discontented users.